Skip to content

Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

By asianet

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall … Continued

MedAlliance SELUTION SLR Receives Second FDA IDE Approval

By asianet

SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). This comes only a few months after the company received IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications … Continued

Novaliq Submits New Drug Application Seeking Approval For First-Of-A-Kind Dry Eye Disease Treatment CyclASol(R)

By asianet

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol(R) water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol(R) (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye … Continued

FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID

By asianet

– FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activity in vitro and in vivo – Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent antiviral concentrations have been reached in the blood plasma and lung tissues without … Continued

HISTORY OF HYPERTENSIVE DISORDERS DURING PREGNANCY LINKED TO INCREASED RISK OF DEMENTIA

By asianet

Experiences of high blood pressure disorders during pregnancy are associated with an increased risk of vascular dementia and accelerated brain aging, according to studies reported today at the Alzheimer’s Association International Conference(R)) (AAIC(R)) 2022 ( https://c212.net/c/link/?t=0&l=en&o=3611257-1&h=4085809890&u=https%3A%2F%2Fwww.alz.org%2Faaic&a=Alzheimer%27s+Association+International+Conference ) in San Diego and virtually. Photo – https://mma.prnewswire.com/media/1871394/AAIC_Vascular_Dementia.jpg Logo – https://mma.prnewswire.com/media/1869584/AAIC22_purple_font_rgb_Logo.jpg Hypertensive disorders of pregnancy (HDP) — conditions … Continued

HIGHLIGHTS FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2022

By asianet

New research reported at the Alzheimer’s Association International Conference(R) ( https://aaic.alz.org/overview.asp ) (AAIC(R)) 2022 covered the breadth of Alzheimer’s and dementia research, including the basic biology of aging and the brain, risk factors and prevention strategies, and caregiving and living well with the disease. Logo – https://mma.prnewswire.com/media/1869584/AAIC22_purple_font_rgb_Logo.jpg AAIC is the premier annual forum for presentation … Continued

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

By asianet

EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for … Continued

LOWER SOCIOECONOMIC STATUS IN CHILDHOOD, PERSISTENT LOW WAGES LINKED TO RISK FOR DEMENTIA AND FASTER MEMORY DECLINE

By asianet

Socioeconomic deprivation, including neighborhood disadvantages and persistent low wages, are associated with higher dementia risk, lower cognitive performance and faster memory decline, according to several studies reported today at the Alzheimer’s Association International Conference(R) (AAIC(R)) 2022 ( https://c212.net/c/link/?t=0&l=en&o=3608645-1&h=3881122162&u=https%3A%2F%2Fwww.alz.org%2Faaic&a=Alzheimer%27s+Association+International+Conference ) in San Diego and virtually. Socioeconomic status (SES) — reflecting both social and economic measures of … Continued

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

By asianet

Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models Context to initiate Phase 1b/2 clinical trial in Q4 2022 Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group (“Menarini”) today … Continued

iHerb Achieves Customer Service Milestones

By asianet

-Users Highly Rate iHerb on Top Online Platforms iHerb, the world’s largest e-commerce platform dedicated to health and wellness, reached significant milestones last month. The company is excited to announce its ratings among Google Customers, Google Play Store, and the Apple App Store. With a 4.9 star rating on Google, 4.8 on Google Play Store … Continued